Univariate analysis for OS and PFS in the overall series
| Characteristics at diagnosis . | N . | 6-year PFS (95% CI) . | P value . | 6-year OS (95% CI) . | P value . |
|---|---|---|---|---|---|
| Age | .20 | .026 | |||
| 17-60 y | 562 | 52% (48-57) | 65% (61-70) | ||
| >60 y | 229 | 47% (40-54) | 58% (51-65) | ||
| Gender | .91 | .93 | |||
| Male | 450 | 51% (46-56) | 63% (58-68) | ||
| Female | 341 | 51% (41-56) | 64% (58-69) | ||
| Diagnosis | .16 | .69 | |||
| DLBCL NOS | 540 | 51% (46-55) | 63% (59-68) | ||
| HG DH/TH | 32 | 42% (24-61) | 62% (43-81) | ||
| HG NOS | 27 | 39% (18-61) | 52% (30-74) | ||
| PMBL | 55 | 63% (50-77) | 67% (54-81) | ||
| Transformed FL | 76 | 36% (24-49) | 57% (44-69) | ||
| DLBCL gray zone | 18 | 64% (41-87) | 82% (63-100) | ||
| DLBCL T-cell rich | 20 | 63% (38-87) | 61% (25-86) | ||
| Other | 8 | 57% (20-94) | 69% (32-100) | ||
| Ann Arbor stage | .86 | .47 | |||
| I-II | 168 | 50% (42-58) | 61% (53-69) | ||
| III-IV | 774 | 51% (47-56) | 64% (60-68) | ||
| B symptoms | .86 | .40 | |||
| No | 405 | 49% (43-54) | 64% (58-69) | ||
| Yes | 354 | 53% (47-58) | 62% (56-67) | ||
| Bulky disease | .4 | .88 | |||
| No | 504 | 49% (44-54) | 63% (59-68) | ||
| Yes | 241 | 54% (47-60) | 63% (56-69) | ||
| Extranodal involvement | .27 | .88 | |||
| No | 286 | 49% (42-55) | 64% (58-70) | ||
| Yes | 464 | 52% (47-57) | 63% (58-67) | ||
| R-IPI | .15 | .015 | |||
| 0 | 42 | 57% (41-73) | 76% (61-91) | ||
| 1-2 | 329 | 52% (46-58) | 67% (62-73) | ||
| 3-5 | 346 | 48% (43-54) | 58% (53-64) | ||
| Response after first line | .23 | .24 | |||
| CR | 443 | 48% (43-53) | 63% (58-68) | ||
| PR | 154 | 54% (45-62) | 65% (57-73) | ||
| SD | 45 | 63% (49-78) | 73% (59-87) | ||
| PD | 149 | 50% (42-59) | 59% (50-68) |
| Characteristics at diagnosis . | N . | 6-year PFS (95% CI) . | P value . | 6-year OS (95% CI) . | P value . |
|---|---|---|---|---|---|
| Age | .20 | .026 | |||
| 17-60 y | 562 | 52% (48-57) | 65% (61-70) | ||
| >60 y | 229 | 47% (40-54) | 58% (51-65) | ||
| Gender | .91 | .93 | |||
| Male | 450 | 51% (46-56) | 63% (58-68) | ||
| Female | 341 | 51% (41-56) | 64% (58-69) | ||
| Diagnosis | .16 | .69 | |||
| DLBCL NOS | 540 | 51% (46-55) | 63% (59-68) | ||
| HG DH/TH | 32 | 42% (24-61) | 62% (43-81) | ||
| HG NOS | 27 | 39% (18-61) | 52% (30-74) | ||
| PMBL | 55 | 63% (50-77) | 67% (54-81) | ||
| Transformed FL | 76 | 36% (24-49) | 57% (44-69) | ||
| DLBCL gray zone | 18 | 64% (41-87) | 82% (63-100) | ||
| DLBCL T-cell rich | 20 | 63% (38-87) | 61% (25-86) | ||
| Other | 8 | 57% (20-94) | 69% (32-100) | ||
| Ann Arbor stage | .86 | .47 | |||
| I-II | 168 | 50% (42-58) | 61% (53-69) | ||
| III-IV | 774 | 51% (47-56) | 64% (60-68) | ||
| B symptoms | .86 | .40 | |||
| No | 405 | 49% (43-54) | 64% (58-69) | ||
| Yes | 354 | 53% (47-58) | 62% (56-67) | ||
| Bulky disease | .4 | .88 | |||
| No | 504 | 49% (44-54) | 63% (59-68) | ||
| Yes | 241 | 54% (47-60) | 63% (56-69) | ||
| Extranodal involvement | .27 | .88 | |||
| No | 286 | 49% (42-55) | 64% (58-70) | ||
| Yes | 464 | 52% (47-57) | 63% (58-67) | ||
| R-IPI | .15 | .015 | |||
| 0 | 42 | 57% (41-73) | 76% (61-91) | ||
| 1-2 | 329 | 52% (46-58) | 67% (62-73) | ||
| 3-5 | 346 | 48% (43-54) | 58% (53-64) | ||
| Response after first line | .23 | .24 | |||
| CR | 443 | 48% (43-53) | 63% (58-68) | ||
| PR | 154 | 54% (45-62) | 65% (57-73) | ||
| SD | 45 | 63% (49-78) | 73% (59-87) | ||
| PD | 149 | 50% (42-59) | 59% (50-68) |
| Characteristics at ASCT . | N . | 6-year PFS (95% CI) . | P value . | 6-year OS (95% CI) . | P value . |
|---|---|---|---|---|---|
| Age at ASCT | .031 | .001 | |||
| 17-60 y | 501 | 54% (50-59) | 67% (63-72) | ||
| >60 y | 290 | 44% (38-51) | 56% (49-62) | ||
| Disease status at salvage therapy | .22 | .85 | |||
| Late relapse | 314 | 49% (42-55) | 63% (57-69) | ||
| Early relapse | 129 | 46% (37-55) | 62% (53-71) | ||
| Primary refractory | 348 | 54% (49-60) | 64% (58-69) | ||
| Time period | .16 | .020 | |||
| Before 30 October 2012 | 163 | 47% (39-54) | 56% (48-64) | ||
| Beyond 1 November 2012 | 628 | 52% (47-56) | 66% (61-70) | ||
| Second-line therapy | .4 | .5 | |||
| R-ESHAP | 442 | 51% (46-56) | 63% (58-68) | ||
| R-DHAP | 48 | 45% (30-59) | 56% (41-71) | ||
| R-ICE | 41 | 65% (50-81) | 75% (60-89) | ||
| R-GDP | 38 | 32% (0-63) | 61% (25-97) | ||
| Other | 195 | 51% (44-59) | 63% (56-71) | ||
| Conditioning regimen | .63 | .97 | |||
| BEAM | 628 | 51% (47-55) | 64% (60-68) | ||
| R-BEAM | 75 | 45% (32-57) | 61% (49-74) | ||
| Z-BEAM | 19 | 47% (22-67) | 58% (36-80) | ||
| TEAM | 4 | 37% (0-93) | 67% (13-100) | ||
| Other | 49 | 62% (48-76) | 66% (52-79) | ||
| Treatment line at ASCT | <.001 | <.001 | |||
| Second line | 617 | 56% (52-60) | 68% (64-72) | ||
| Third line | 147 | 33% (25-41) | 45% (36-54) | ||
| Front line in transformed | 27 | 28% (8-47) | 55% (33-76) | ||
| Pre-ASCT response | <.001 | <.001 | |||
| CR | 481 | 56% (52-61) | 69% (64-73) | ||
| PR | 275 | 43% (37-50) | 57% (50-63) | ||
| SD/PD | 21 | 35% (14-57) | 40% (15-64) |
| Characteristics at ASCT . | N . | 6-year PFS (95% CI) . | P value . | 6-year OS (95% CI) . | P value . |
|---|---|---|---|---|---|
| Age at ASCT | .031 | .001 | |||
| 17-60 y | 501 | 54% (50-59) | 67% (63-72) | ||
| >60 y | 290 | 44% (38-51) | 56% (49-62) | ||
| Disease status at salvage therapy | .22 | .85 | |||
| Late relapse | 314 | 49% (42-55) | 63% (57-69) | ||
| Early relapse | 129 | 46% (37-55) | 62% (53-71) | ||
| Primary refractory | 348 | 54% (49-60) | 64% (58-69) | ||
| Time period | .16 | .020 | |||
| Before 30 October 2012 | 163 | 47% (39-54) | 56% (48-64) | ||
| Beyond 1 November 2012 | 628 | 52% (47-56) | 66% (61-70) | ||
| Second-line therapy | .4 | .5 | |||
| R-ESHAP | 442 | 51% (46-56) | 63% (58-68) | ||
| R-DHAP | 48 | 45% (30-59) | 56% (41-71) | ||
| R-ICE | 41 | 65% (50-81) | 75% (60-89) | ||
| R-GDP | 38 | 32% (0-63) | 61% (25-97) | ||
| Other | 195 | 51% (44-59) | 63% (56-71) | ||
| Conditioning regimen | .63 | .97 | |||
| BEAM | 628 | 51% (47-55) | 64% (60-68) | ||
| R-BEAM | 75 | 45% (32-57) | 61% (49-74) | ||
| Z-BEAM | 19 | 47% (22-67) | 58% (36-80) | ||
| TEAM | 4 | 37% (0-93) | 67% (13-100) | ||
| Other | 49 | 62% (48-76) | 66% (52-79) | ||
| Treatment line at ASCT | <.001 | <.001 | |||
| Second line | 617 | 56% (52-60) | 68% (64-72) | ||
| Third line | 147 | 33% (25-41) | 45% (36-54) | ||
| Front line in transformed | 27 | 28% (8-47) | 55% (33-76) | ||
| Pre-ASCT response | <.001 | <.001 | |||
| CR | 481 | 56% (52-61) | 69% (64-73) | ||
| PR | 275 | 43% (37-50) | 57% (50-63) | ||
| SD/PD | 21 | 35% (14-57) | 40% (15-64) |
Boldface values statistical significance.